ValuEngine upgraded shares of Vascular Biogenics (NASDAQ:VBLT) from a sell rating to a hold rating in a report released on Friday.
Other research analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Vascular Biogenics from a sell rating to a hold rating in a research report on Saturday, January 6th. HC Wainwright restated a buy rating and issued a $11.00 target price on shares of Vascular Biogenics in a research report on Tuesday, November 21st. Finally, Chardan Capital upped their target price on shares of Vascular Biogenics from $20.00 to $25.00 and gave the stock a buy rating in a research report on Monday, November 6th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $15.67.
Shares of Vascular Biogenics (NASDAQ:VBLT) opened at $6.35 on Friday. The firm has a market cap of $188.75, a PE ratio of -8.04 and a beta of -2.87. Vascular Biogenics has a 12 month low of $3.90 and a 12 month high of $9.05.
Vascular Biogenics (NASDAQ:VBLT) last released its quarterly earnings data on Tuesday, November 14th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.04). research analysts expect that Vascular Biogenics will post -0.9 earnings per share for the current fiscal year.
An institutional investor recently raised its position in Vascular Biogenics stock. IFP Advisors Inc increased its stake in Vascular Biogenics Ltd (NASDAQ:VBLT) by 339.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,567 shares of the biopharmaceutical company’s stock after acquiring an additional 15,117 shares during the period. IFP Advisors Inc owned approximately 0.07% of Vascular Biogenics worth $139,000 at the end of the most recent reporting period. 6.59% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Vascular Biogenics (VBLT) Raised to Hold at ValuEngine” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/05/vascular-biogenics-vblt-raised-to-hold-at-valuengine.html.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.